Neuralstem: NSI-189 Phase 2 Trial Fails To Meet Primary Efficacy Endpoint

(RTTNews) - Neuralstem, Inc. (CUR) announced top-line results from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189 at 40 mg once daily and 40 mg twice daily compared to placebo for the treatment of major depressive disorder. The study, which utilized the two-staged sequential parallel comparison design, did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale.

Rich Daly, chairman and CEO, Neuralstem, said: "The directionally positive signals across multiple depression scales are encouraging and we look forward to further evaluation of the full dataset in the coming months."